641 Assessing Sexual Function Outcomes Following Optilume BPH Use for Lower Urinary Tract Symptoms: A Systematic Review
Abstract
Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) in men can significantly impair quality of life, including sexual function. Optilume BPH, a drug-coated balloon catheter, has emerged as a potential treatment option for managing bladder outlet obstruction (BOO) due to BPH. This systematic review examines the impact of Optilume BPH on sexual function outcomes in men with LUTS secondary to BPH.
A systematic search was conducted across different databases. Studies were included if they assessed sexual function using validated tools such as the International Index of Erectile Function (IIEF) or the Male Sexual Health Questionnaire (MSHQ) in patients undergoing Optilume BPH. Studies involving other causes of LUTS, alternative surgical or minimally invasive treatments, or non-sexual function metrics were excluded. Study designs included RCTs, observational studies, case series and case reports.
Of 141 studies screened; 2 met the inclusion criteria. A RCT (n = 148; 99 treated with Optilume BPH) showed IIEF-OS scores improved from 5.6 ± 2.7 (n = 96) to 6.5 ± 2.9 (N = 72), IIEF from 15.6 ± 10.3 to 20.4 ± 10.2 and MSHQ-EjD scores from 7.5 ± 3.9 to 8.6 ± 4.6 at 2 years. A single-arm study (n = 80) showed IIEF (17.6±11.0-16.3±10.8) and MSHQ scores were preserved at 4 years. Both studies demonstrated clinically significant LUTS and sexual function improvements. Adverse events, primarily haematuria and UTIs were minimal.
Data from early studies show…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 148 participants or records.
Read the paper
Related studies
- Erectile dysfunction
- Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit
- Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
- Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets
- Chronic bladder ischemia and oxidative stress: New pharmacotherapeutic targets for lower urinary tract symptoms
- The role of prostate inflammation and fibrosis in lower urinary tract symptoms
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.